Search

everythinglearnresearchcommunity

for

Search:↓

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

Hair loss treatments that avoid significantly lowering systemic DHT levels, focusing on topical options like dutasteride mesotherapy, minoxidil, and ketoconazole. The user is exploring alternatives like KX-826 and RU58841 due to concerns about hormone levels.

The conversation is about hair loss treatments, including dermarolling, Minoxidil, Finasteride, and RU58841. Users discuss their experiences, side effects, and application methods for these treatments.

The user has been using dutasteride and finasteride but still experiences hair loss and high DHT levels. They plan to try topical finasteride and RU58841 while continuing dutasteride to see if topicals are more effective.

Dutasteride and finasteride for hair loss, with dissatisfaction expressed about dutasteride and consideration of switching back to finasteride. Users share varied experiences, noting individual responses to treatments differ.

TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.

The conversation is about the use of peptide therapies for hair loss, specifically GHK-CU, ZN-Thymulin, and PTD-DBM. The user is seeking feedback on the effectiveness of these treatments from those who have tried them.

The conversation discusses the use of topical finasteride for hair loss, with the user considering whether oral finasteride might be more effective in reducing DHT levels. Other users suggest alternatives like dutasteride, RU58841, saw palmetto, and a combination of Redensyl, Procapil, and Capixyl, while debating the effectiveness and side effects of these treatments.

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.

The conversation is about seeking user experiences with Traya for hair loss treatment, focusing on the effectiveness and convenience of its doctor, diet, and product approach. The user is conducting research and requests feedback on what worked or didn't work.

A user is considering combining oral and topical dutasteride to lower scalp DHT more effectively and is seeking advice on this approach. They are thinking about doing a patch test on their mid scalp.

The conversation discusses the effects of lowering DHT on hair loss and the importance of monitoring DHT levels during treatment. The user suggests that individual responses to DHT and hair loss treatments vary, and expresses a preference for topical treatments over oral medications due to concerns about systemic DHT reduction.

The conversation discusses using very low dose topical finasteride to achieve specific serum DHT reduction percentages. It concludes that finasteride dosage increases linearly between 5-30% DHT reduction but requires exponential increases for reductions up to 70%.

The conversation discusses using finasteride, dutasteride, RU58841, and testosterone to combat hair loss and block DHT, with some users expressing concerns about side effects and vegan options for medication. The discussion also touches on personal experiences with hormone treatments and the desire to maintain a youthful appearance.

SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.

The conversation is about hair loss treatments, specifically the anticipation for the release of a new treatment, GT20029, by 2028. Users are discussing their experiences with current treatments like finasteride and dutasteride, and the potential of future treatments, including FAK inhibitors and verteporfin trials.

Mesotherapy for hair loss, including treatments like finasteride and dutasteride, is discussed, with some users reporting pain and mixed results. Alternatives like PRP injections and topical treatments such as minoxidil, RU58841, and tretinoin are also mentioned as effective options.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

The conversation discusses new hair loss treatments like stem cell therapy, exosome treatments, and DHI, with mentions of GT20029, Amp303, and Plated PRP Serum as promising options. It also notes the use of dutasteride, topical finasteride, and minoxidil, but the focus is on non-hormonal innovations.

User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.

Users discuss alternatives to DHT blockers for hair loss, suggesting minoxidil, microneedling, natural DHT blockers, and scalp massages. Some explore RU58841, ketoconazole, hair transplants, and hair systems due to side effects from finasteride and dutasteride.

The conversation is about using PTD-DBM and valproic acid for hair loss. The user is inquiring about the dosage of these treatments, noting that valproic acid is used at a 7.5% solution.

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

The conversation discusses hair loss treatments like topical finasteride with minoxidil, oral dutasteride, and essential oils. Oral treatments like dutasteride and finasteride are seen as more effective, though some prefer topicals to avoid side effects.

User "logart89" claims DUT 3 times a week is better than daily FIN for hair loss. Their routine includes DUT, topical DUT, stemoxydine and alfatradiol mix, 5% minoxidil with tretinoin, and weekly derma stamping.

A user is making their own dutasteride solution using MCT oil but is concerned about its effectiveness and bioavailability. They are considering using propylene glycol or adding ethanol for better results, while others suggest the current dosage might be excessive.

The conversation discusses the use of finasteride for hair loss, with OP considering switching to dutasteride due to concerns about effectiveness. Users share experiences and concerns about side effects, including potential impacts on fertility.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.